NCT06764589Active, not recruiting
Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood
Source: ClinicalTrials.gov · Last updated 8 Jan 2025
Brief summary (registry, in English)
This is a prospective multicentre, tissue-based, non-profit study that includes two enrolling centres: Operating Unit (OU) No. 1 of Haematology and OU No. 2 of Medical Oncology, both at the IRCCS Azienda Ospedaliera-Universitaria di Bologna (AOUBO). Given the rarity of the pathology investigated and the lack of evidence from the literature, the study should be considered exploratory, aimed at providing provisional evidence and generating hypotheses that could be tested in future studies. The study involves the collection of peripheral blood samples from healthy volunteers (HD) matched for sex/age (n=30; Group 1) and patients with acute myeloid leukaemia at diagnosis (n=30; Group 2) at UO1 and patients with visceral sarcoma with measurable disease (n=30; Group 3) at UO2. Specifically, peripheral blood (equal to 60 mL) from healthy volunteers will be collected after obtaining the signed informed consent of the volunteers of the Associazione Onlus AIL Bologna ODV. From all participants in Groups 2 and 3, 60 mL of peripheral blood and 20 mL of bone marrow blood will be collected at routine clinical examinations. Bone biopsies (10 sections) will also be collected from Group 2 patients. All samples will be collected at the time of diagnosis (T0). All samples will be centralised at the Haematology Unit, IRCCS AOUBO and submitted for laboratory analysis. For patients with acute myeloid leukaemia, responses to treatment will be assessed on the basis of standard criteria according to the recommendations of the European LeukemiaNet of 2022 (Döhner H et al, Blood 2022). Clinical response for sarcoma patients according to the international RECIST imaging criteria assessed by routine computed tomography or magnetic resonance imaging scans.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 2 Jan 2025
- Start date
- 16 Dec 2024
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06764589
What you commit to
- Study type: Observational
- Planned participants: 90
- From 16 Dec 2024 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- For HD:
- None
- For AML and sarcoma patients:
- Acute promyelocytic leukemia (for AML)
- Known AML with central nervous system involvement (for AML)
- Visceral sarcoma in adjuvant setting (for sarcoma)
Who the study is looking for
- For HD:
- Age ≥ 18 years
- Volunteer in general good health, free from any disease or serious illness
- Signed written informed consent to study participation and personal data processing
- For AML patients:
- Age ≥ 18 years
- New diagnosis of AML according to World Health Organization 2022 criteria
- Front-line treatment according to routine clinical practice
- Signed written informed consent to study participation and personal data processing
- For sarcoma patients:
- Age ≥ 18 years
- Diagnosis of visceral soft tissue sarcoma according to World Health Organization 2021 criteria in metastatic setting
- Signed written informed consent to study participation and personal data processing
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.